Aj PakpourFounder, Business Of Modern Medicine · Aj Pakpour | The Business Of Modern Medicine |

The Truth About Retatrutide: What They’re Not Telling You

16 Sept 2026 · 1 min

Watch on YouTube

1:00

In this video, the creator explains that retatrutide, a triple‑agonist drug targeting GLP‑1, GIP, and glucagon receptors, has generated massive public interest as a potential weight‑loss breakthrough. Clinical trial data show it can produce weight loss comparable to bariatric surgery and outperform currently approved drugs such as Ozempic and Mounjaro. However, retatrutide is still investigational and has not received FDA approval. Despite this, social‑media platforms are flooded with dosing discussions and self‑reported, unregulated use, illustrating a gap where public demand is outpacing the slower pace of formal drug development and regulatory review. The video calls attention to the need for a measured conversation about the risks of premature adoption of an unapproved therapy.

Chapters

Retatrutide is becoming America's most talked about weight loss drug, but here is the catch. It isn't FDA approved yet. It's still being studied. Yet somehow it is already everywhere. It is a triple agonist targeting three hormone receptors: GLP-1, GIP, and glucagon. Clinical trials show weight loss comparable to surgery. Outperforming established drugs like Ozempic or Mounjaro. But while those are approved, retatrutide remains investigational, yet demand is exploding across the internet. Social media is full of dosing discussions and people documenting their own unregulated experiences. We are watching what happens when public demand moves faster than traditional drug development. Headlines move at light speed, But science takes time. That is the conversation worth having.